Ładuje się......
Pembrolizumab-induced Myositis in the Setting of Metastatic Melanoma: An Increasingly Common Phenomenon
Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody, has demonstrated efficacy in treating metastatic melanoma. However, a handful of case reports have been published reporting autoimmune phenomena weeks after administration of the first dose of this immunomodulator. Although immu...
Zapisane w:
| Wydane w: | J Clin Aesthet Dermatol |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Matrix Medical Communications
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7442312/ https://ncbi.nlm.nih.gov/pubmed/32884619 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|